vs
Side-by-side financial comparison of GRID DYNAMICS HOLDINGS, INC. (GDYN) and NATURES SUNSHINE PRODUCTS INC (NATR). Click either name above to swap in a different company.
NATURES SUNSHINE PRODUCTS INC is the larger business by last-quarter revenue ($123.8M vs $104.1M, roughly 1.2× GRID DYNAMICS HOLDINGS, INC.). NATURES SUNSHINE PRODUCTS INC runs the higher net margin — 3.3% vs -1.4%, a 4.7% gap on every dollar of revenue. On growth, NATURES SUNSHINE PRODUCTS INC posted the faster year-over-year revenue change (4.7% vs 3.7%). Over the past eight quarters, GRID DYNAMICS HOLDINGS, INC.'s revenue compounded faster (12.0% CAGR vs 5.6%).
Escape Dynamics, Inc. was a Colorado-based technology company that operated 2010–2015 focused on bringing to market single-stage-to-orbit reusable electromagnetically powered spaceplanes.
Nature's Sunshine Products, Inc. also known as "NSP", is a manufacturer of dietary supplements, including herbs, vitamins, minerals, and personal care products. It is based in Lehi, Utah, with a manufacturing facility in Spanish Fork, Utah.
GDYN vs NATR — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $104.1M | $123.8M |
| Net Profit | $-1.5M | $4.1M |
| Gross Margin | 34.8% | 72.5% |
| Operating Margin | 61.7% | 4.3% |
| Net Margin | -1.4% | 3.3% |
| Revenue YoY | 3.7% | 4.7% |
| Net Profit YoY | -150.6% | 1379.4% |
| EPS (diluted) | $-0.02 | $0.23 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $104.1M | — | ||
| Q4 25 | $106.2M | $123.8M | ||
| Q3 25 | $104.2M | $128.3M | ||
| Q2 25 | $101.1M | $114.8M | ||
| Q1 25 | $100.4M | $113.2M | ||
| Q4 24 | $100.3M | $118.2M | ||
| Q3 24 | $87.4M | $114.6M | ||
| Q2 24 | $83.0M | $110.6M |
| Q1 26 | $-1.5M | — | ||
| Q4 25 | $306.0K | $4.1M | ||
| Q3 25 | $1.2M | $5.3M | ||
| Q2 25 | $5.3M | $5.3M | ||
| Q1 25 | $2.9M | $4.7M | ||
| Q4 24 | $4.5M | $-321.0K | ||
| Q3 24 | $4.3M | $4.3M | ||
| Q2 24 | $-817.0K | $1.3M |
| Q1 26 | 34.8% | — | ||
| Q4 25 | 34.0% | 72.5% | ||
| Q3 25 | 33.3% | 73.3% | ||
| Q2 25 | 34.1% | 71.7% | ||
| Q1 25 | 36.8% | 72.1% | ||
| Q4 24 | 36.9% | 72.0% | ||
| Q3 24 | 37.4% | 71.3% | ||
| Q2 24 | 35.6% | 71.4% |
| Q1 26 | 61.7% | — | ||
| Q4 25 | 0.5% | 4.3% | ||
| Q3 25 | -0.2% | 7.0% | ||
| Q2 25 | -0.1% | 3.7% | ||
| Q1 25 | -2.0% | 5.4% | ||
| Q4 24 | 1.3% | 3.8% | ||
| Q3 24 | 2.4% | 4.6% | ||
| Q2 24 | 0.0% | 5.1% |
| Q1 26 | -1.4% | — | ||
| Q4 25 | 0.3% | 3.3% | ||
| Q3 25 | 1.1% | 4.2% | ||
| Q2 25 | 5.2% | 4.6% | ||
| Q1 25 | 2.9% | 4.2% | ||
| Q4 24 | 4.5% | -0.3% | ||
| Q3 24 | 4.9% | 3.8% | ||
| Q2 24 | -1.0% | 1.2% |
| Q1 26 | $-0.02 | — | ||
| Q4 25 | $0.01 | $0.23 | ||
| Q3 25 | $0.01 | $0.30 | ||
| Q2 25 | $0.06 | $0.28 | ||
| Q1 25 | $0.03 | $0.25 | ||
| Q4 24 | $0.06 | $-0.02 | ||
| Q3 24 | $0.05 | $0.23 | ||
| Q2 24 | $-0.01 | $0.07 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $327.5M | $93.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $530.1M | $161.6M |
| Total Assets | $605.0M | $261.1M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $327.5M | — | ||
| Q4 25 | $342.1M | $93.9M | ||
| Q3 25 | $338.6M | $95.6M | ||
| Q2 25 | $336.8M | $81.3M | ||
| Q1 25 | $325.5M | $86.5M | ||
| Q4 24 | $334.7M | $84.7M | ||
| Q3 24 | $231.3M | $78.7M | ||
| Q2 24 | $256.0M | $68.7M |
| Q1 26 | $530.1M | — | ||
| Q4 25 | $542.1M | $161.6M | ||
| Q3 25 | $537.7M | $166.7M | ||
| Q2 25 | $532.2M | $163.7M | ||
| Q1 25 | $517.4M | $167.1M | ||
| Q4 24 | $517.8M | $161.0M | ||
| Q3 24 | $400.2M | $162.6M | ||
| Q2 24 | $388.4M | $156.4M |
| Q1 26 | $605.0M | — | ||
| Q4 25 | $612.9M | $261.1M | ||
| Q3 25 | $613.2M | $264.8M | ||
| Q2 25 | $608.9M | $254.9M | ||
| Q1 25 | $590.9M | $252.7M | ||
| Q4 24 | $592.2M | $240.9M | ||
| Q3 24 | $477.3M | $245.3M | ||
| Q2 24 | $443.6M | $235.8M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $9.9M |
| Free Cash FlowOCF − Capex | — | $7.6M |
| FCF MarginFCF / Revenue | — | 6.1% |
| Capex IntensityCapex / Revenue | — | 1.9% |
| Cash ConversionOCF / Net Profit | — | 2.41× |
| TTM Free Cash FlowTrailing 4 quarters | — | $28.8M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $9.9M | $9.9M | ||
| Q3 25 | $7.0M | $18.5M | ||
| Q2 25 | $14.4M | $4.3M | ||
| Q1 25 | $9.4M | $2.6M | ||
| Q4 24 | $7.1M | $12.2M | ||
| Q3 24 | $9.2M | $9.6M | ||
| Q2 24 | $10.7M | $1.3M |
| Q1 26 | — | — | ||
| Q4 25 | $6.1M | $7.6M | ||
| Q3 25 | $2.9M | $16.8M | ||
| Q2 25 | $10.2M | $3.0M | ||
| Q1 25 | $6.0M | $1.5M | ||
| Q4 24 | $4.4M | $10.0M | ||
| Q3 24 | $5.9M | $7.9M | ||
| Q2 24 | $8.0M | $-2.0M |
| Q1 26 | — | — | ||
| Q4 25 | 5.7% | 6.1% | ||
| Q3 25 | 2.8% | 13.1% | ||
| Q2 25 | 10.1% | 2.6% | ||
| Q1 25 | 6.0% | 1.3% | ||
| Q4 24 | 4.4% | 8.5% | ||
| Q3 24 | 6.8% | 6.9% | ||
| Q2 24 | 9.7% | -1.9% |
| Q1 26 | — | — | ||
| Q4 25 | 3.6% | 1.9% | ||
| Q3 25 | 3.9% | 1.3% | ||
| Q2 25 | 4.1% | 1.2% | ||
| Q1 25 | 3.3% | 1.0% | ||
| Q4 24 | 2.6% | 1.9% | ||
| Q3 24 | 3.7% | 1.5% | ||
| Q2 24 | 3.2% | 3.0% |
| Q1 26 | — | — | ||
| Q4 25 | 32.34× | 2.41× | ||
| Q3 25 | 5.92× | 3.46× | ||
| Q2 25 | 2.73× | 0.81× | ||
| Q1 25 | 3.21× | 0.55× | ||
| Q4 24 | 1.56× | — | ||
| Q3 24 | 2.15× | 2.21× | ||
| Q2 24 | — | 0.97× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GDYN
Segment breakdown not available.
NATR
| Other | $68.1M | 55% |
| General Health Products | $20.2M | 16% |
| Digestive Products | $13.8M | 11% |
| Cardiovascular Products | $12.1M | 10% |
| Personal Care Products | $4.4M | 4% |
| Immunity Products | $3.1M | 3% |
| Weight Management Products | $2.1M | 2% |
